2025

Autoantibody origins in lupus and in relapse post CAR-T therapy

Grenov A, Yoon J, Snell DM, Mikolajczak A, Wang H, Gürel E, Rodriguez Ronchel A, Yegen G, Lee L, Artim Esen B, Rahman A, Maciocia P, Vinuesa CG

bioRxiv 2025 [Preprint]

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

Maciocia N, Hoekx M, Acuna C, Wade B, Burley A, Ramanayake S, Nannini F, Wawrzyniecka PA, Karpanasamy T, Schuldt M, Ng S, Ferrari M, Marafioti T, Gritti G, Onuoha S, O'Connor D, Lee L, Mansour M, Khwaja A, Pule M, Maciocia P

Science Translational Medicine 2025; 17(794)

Reply to: Oligoclonality of TRBC1 and TRBC2 in T cell lymphomas

Ferrari M, Parekh F, Maciocia P, Horna P, Thomas S, Sewell AK, Pule M

Nature Communications 2025; 16(1)

CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?

Maciocia N, Wade B, Maciocia P

Blood Advances 2025; 9(4):913-925

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine DA, Balasubramaniam N, Wood L, Shang J, Xue E, Zhang Y, Basilico S, Neves M, Raymond M, Scott I, El-Kholy M, Jha R, Dainton-Smith H, Hussain R, Day W, Ferrari M, Thomas S, Lilova K, Brugger W, Marafioti T, Lao-Sirieix P, Maciocia P, Pule M

Nature Medicine 2025; 31(1):76-86

In situ tracking of TCR-beta isoforms for detection of T cell clonality

Manipadam MT, Marra A, Ramsay A, Padmasri S, Gosh A, Neves M, Bailey C, Pomplun S, Maciocia P, Cwynarski K, Ferrari M, Lao-Siriex P, Piris M, Falini B, Linch D, Rosenwald A, Pule M, Zamo A, Marafioti T

Hematological Oncology 2025; 43(1):e70018

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation

Hwang A, Kirkwood AA, O'Reilly M, Neill L, Besley C, Paneesha S, Amrith M, Maciocia P, Kuhnl A, Irvine D, Norman J, Abdulgawad A, Gonzalez Arias C, Iyengar S, Marr H, Gohil S, Roddie C

British Journal of Haematology 2025; 207(2):648-653

2024

Single-centre experience of physiotherapist-led prehabilitation for chimeric antigen receptor T cell therapy

McCourt O, Maciocia P, Roddie C, Hwang A, Wood L, Panopoulou A, Springell DA, Al Bakir M, O'Reilly M

eJHaem 2024; 5(5):1062-1066

Dual T-cell constant beta chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

Horna P, Weybright MJ, Ferrari M, Jungherz D, Peng Y, Akbar Z, Tudor Ilca F, Otteson GE, Seheult JN, Ortmann J, Shi M, Maciocia PM, Herling M, Pule MA, Olteanu H

Blood Cancer Journal 2024; 14(1):34

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies

Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, Ma B, Bughda R, Akbar Z, Srivastava S, Gannon I, Robson M, Sillibourne J, Jha R, El-Kholy M, Amin OM, Kokalaki E, Banani MA, Hussain R, Day W, Lim WC, Ghongane P, Hopkins JR, Jungherz D, Herling M, Welin M, Surade S, Dyson M, McCafferty J, Logan D, Cordoba S, Thomas S, Sewell A, Maciocia P, Onuoha S, Pule M

Nature Communications 2024; 15:1-19

2022

A Novel Protein-Based Approach to Generate Allogeneic CAR-T Cells with Simultaneous TCR and MHC Class 1 Downregulation

Karpanasamy T, Wawrzyniecka P, Devereaux S, Kassimatis L, Maciocia NC, Pule M, Maciocia PM

Blood 2022; 140(Supplement 1):636–637 [ASH Abstract]

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Maciocia PM, Wawrzyniecka PA, Maciocia NC, Burley A, Karpanasamy T, Devereaux S, Hoekx M, O'Connor D, Leon T, Rapoz-D'Silva T, Pocock R, Rahman S, Gritti G, Yanez DC, Ross S, Crompton T, Williams O, Lee L, Pule MA, Mansour MR

Blood 2022; 140(1):25-37

Chimeric antigen receptor T cells for gamma-delta T cell malignancies

Wawrzyniecka PA, Ibrahim L, Gritti G, Pule MA, Maciocia PM

Leukemia 2022; 36(2):577-579

2019

Anti-CD1a CAR T cells to selectively target T-ALL

Maciocia PM, Pule MA

Blood 2019; 133(21):2246-2247

2018

A Protein-Based Method to Develop Allogeneic Chimeric Antigen Receptor T-Cells

Maciocia P, Wawrzyniecka P, Kassimatis L, Pule M

Blood 2018; 132(Supplement 1):700 [ASH Abstract]

2017

Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA

Nature Medicine 2017; 23(12):1416-1423

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma

Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S, Maciocia P, Popat R, D'sa S, Rismani A, Cerner A, Yong K, Rabin N

British Journal of Haematology 2017; 176(6):908-917

2016

Treatment of diffuse large B-cell lymphoma with secondary CNS involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy

Maciocia P, Badat M, Cheesman S, D'Sa S, Joshi R, Lambert J, Mohamedbhai S, Pule M, Linch D, Ardeshna K

British Journal of Haematology 2016; 172(4):545-553